Co-Pay Assistance for Lotronex

Okay, okay, I admit I am a little late in coming to the party. Apparently Promethus Laboratories, Inc. put out a press release (Reuters) on September 9th of this year announcing a co-pay assistance program for patients who are taking Lotronex (alosetron). This financial assistance program is available to any patients who meet the strict prescription guidelines for Lotronex.

Lotronex is the only FDA approved medication for the treatment of diarrhea-predominant IBS (IBS-D). Due to concerns about serious side effects, Lotronex is only available to women who have chronic, severe IBS-D symptoms who have not responded to other forms of treatment and who have no history of constipation.

Under the new savings program, patients are only responsible for the first $50 of their copay. Following this, patients are eligible to receive savings up to $250. This program is in addition to Prometheus' policy of providing a voucher for a two-week sample to new patients.

In these days of financial hardship, I am sure that any help is appreciated. It just blows the mind that the savings plan reduces the co-pay to $50. I shudder to think what the total co-pay is! Unfortunately, illness often comes with a high financial price, in addition to the toll it takes on quality of life. As I am not a political person, I will leave it at that and let the health care reform individuals take the conversation from here!

Related Reading:

• Medication for Diarrhea